

Foluso O Ademuyiwa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5633774/publications.pdf>

Version: 2024-02-01

53
papers

3,301
citations

186265
28
h-index

197818
49
g-index

56
all docs

56
docs citations

56
times ranked

7099
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
2	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	21.4	374
3	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	21.4	279
4	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4055-4065.	7.0	243
5	Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1925.	7.4	219
6	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6240-6249.	0.9	109
7	19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus. <i>Cancer Research</i> , 2012, 72, 1795-1803.	0.9	100
8	The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 797-802.	2.5	99
9	Impact of body mass index on clinical outcomes in triple-negative breast cancer. <i>Cancer</i> , 2011, 117, 4132-4140.	4.1	86
10	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1583-1591.	7.0	86
11	NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e38783.	2.5	85
12	Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. <i>Breast Cancer Research</i> , 2012, 14, R58.	5.0	75
13	Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. <i>Modern Pathology</i> , 2012, 25, 388-397.	5.5	69
14	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	7.0	66
15	Breast Cancer Racial Disparities: Unanswered Questions. <i>Cancer Research</i> , 2011, 71, 640-644.	0.9	64
16	Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. <i>EBioMedicine</i> , 2020, 59, 102963.	6.1	63
17	Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 491-499.	2.5	59
18	Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer. <i>Annals of Surgery</i> , 2016, 264, 1098-1102.	4.2	53

#	ARTICLE	IF	CITATIONS
19	CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2473-2485.	4.1	51
20	Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 550-562.	6.4	48
21	Prognostic Factors in Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2007, 8, 478-482.	2.6	47
22	Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging. <i>Journal of Biomedical Optics</i> , 2018, 24, 1.	2.6	46
23	Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. <i>Histopathology</i> , 2012, 61, 365-377.	2.9	44
24	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. <i>Modern Pathology</i> , 2010, 23, 270-275.	5.5	43
25	US breast cancer mortality trends in young women according to race. <i>Cancer</i> , 2015, 121, 1469-1476.	4.1	43
26	Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. <i>PLoS ONE</i> , 2019, 14, e0222358.	2.5	35
27	Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 NO Breast Cancer and Normal Axillary Ultrasound. <i>Journal of the American College of Surgeons</i> , 2016, 223, 399-407.	0.5	30
28	Time-trends in survival in young women with breast cancer in a SEER population-based study. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 241-248.	2.5	29
29	Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. <i>Clinical Breast Cancer</i> , 2016, 16, 471-479.e1.	2.4	29
30	Immunogenomic Profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 187-202.	2.5	24
31	Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. <i>Modern Pathology</i> , 2010, 23, 1364-1378.	5.5	21
32	Managing breast cancer in younger women: challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 1.	1.8	20
33	Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. <i>Journal of Clinical Oncology</i> , 2021, 39, 4020-4028.	1.6	20
34	Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 151-159.	2.5	17
35	Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer. <i>Journal of Oncology</i> , 2013, 2013, 1-8.	1.3	15
36	The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2009, 21, 110-115.	2.4	14

#	ARTICLE	IF	CITATIONS
37	Incorporation of Antiangiogenic Therapies in the Treatment of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, S151-S156.	2.4	13
38	Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 288-296.	4.9	13
39	Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. <i>Journal of Geriatric Oncology</i> , 2012, 3, 320-328.	1.0	12
40	Racial differences in no-show rates for screening mammography. <i>Cancer</i> , 2021, 127, 1857-1863.	4.1	11
41	Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 113-123.	1.8	10
42	ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. <i>Modern Pathology</i> , 2011, 24, 1055-1059.	5.5	9
43	Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 109-126.	1.5	9
44	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. <i>Human Genetics</i> , 2016, 135, 137-154.	3.8	8
45	A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. <i>Npj Breast Cancer</i> , 2022, 8, 35.	5.2	7
46	Characteristics of male triple negative breast cancer: A population-based study. <i>Breast Journal</i> , 2020, 26, 1748-1755.	1.0	5
47	An 81-Year-Old Patient With Distant Metastasis of Invasive Lobular Carcinoma Occurring 41 Years After Mastectomy. <i>Clinical Breast Cancer</i> , 2012, 12, 293-295.	2.4	2
48	Comparative Effectiveness of Biomarkers to Target Cancer Treatment. <i>Medical Decision Making</i> , 2016, 36, 594-603.	2.4	2
49	Cetuximab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 107-113.	3.1	1
50	Updates on Molecular Classification of Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2018, 10, 289-295.	1.0	1
51	Importance of Biosy of a Presumed Solitary Skeletal Metastasis: Enchondroma in a Breast Cancer Patient. <i>Breast Journal</i> , 2012, 18, 172-174.	1.0	0
52	Reply to differences in 25-hydroxyvitamin D concentrations may explain most of the black-white breast cancer disparities noted in young women. <i>Cancer</i> , 2015, 121, 2098-2098.	4.1	0
53	Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i). <i>Cancer Research</i> , 2022, 82, P2-07-01-P2-07-01.	0.9	0